Description
Acetyl-CoA carboxylase 1 (ACC1) is a biotin-dependent enzyme that catalyzes the conversion of acetyl CoA (Item No. 16160) to malonyl CoA (Item No. 16455), a building block in the biosynthesis of long-chain fatty acids.{60043,60044,60045} It is found at high levels in the liver and adipose tissue and is localized to the cytosol.{60045} Expression of ACC1 is increased by sterol regulatory element binding protein-1a (SREBP-1a) and SREBP-1c, which are induced by insulin, as well as the lipid precursors inositol and choline (Item No. 31178).{60043} ACC1 activity is increased by citrate and inhibited by binding to long-chain acyl-CoAs or by phosphorylation by a number of kinases, including AMPK and TAK1.{60043,60045,60046} Acetyl-CoA carboxylase 1 has critical roles in fatty acid synthesis and regulation of insulin levels.{60045} It is involved in numerous pathological conditions, including metabolic diseases such as diabetes and non-alcoholic fatty liver disease (NAFLD), as well as cancer and bacterial infections.{60044} Cayman’s Acetyl-CoA Carboxylase 1 Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.
Synonyms: ACC1|ACCα
Immunogen: Peptide corresponding to human ACC1
Formulation: 100 µl of protein A-affinity purified monoclonal antibody
Isotype: IgG
Applications: IHC, WB
Origin:
Stability: 365 days
Application|Immunohistochemistry||Application|Western Blot||Product Type|Antibodies|Monoclonal Antibodies||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Endocrinology & Metabolism|Nutrient Sensing||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases||Research Area|Lipid Biochemistry|Acyl-CoAs||Research Area|Lipid Biochemistry|Fatty Acids|Degradation||Research Area|Lipid Biochemistry|Fatty Acids|Synthesis
